Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)

NCT04322318 is registered in ClinicalTrials.gov with Children's Oncology Group as lead sponsor.

NCT NCT04322318
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04322318 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)
Lead sponsor
Children's Oncology Group
Phase
Phase 2
Overall status
Recruiting
Start date
October 19, 2020
Completion date
July 1, 2027
Enrollment
256 (estimated)
Sites
205

Conditions

As the registry lists them; a condition with its own page is linked.

anaplastic kidney wilms tumor, recurrent kidney wilms tumor, stage ii kidney wilms tumor, stage iii kidney wilms tumor, stage iv kidney wilms tumor